Clinical Trial Update: Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults [Phase 4]

View source ↗

Summary

This Phase 4 trial assessed the humoral immune response to the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in immunocompromised adults compared with healthy adu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hematologic Malignancy
• Hypergammaglobulinemia
• Malignant Neoplasm
• Multiple Myeloma
• Multiple Sclerosis
• Type 2 Diabetes Mellitus

Drugs mentioned

• Comirnaty (BNT162b2) (tozinameran)

Snippet

Sponsor: Centre Hospitalier Régional d'Orléans | Conditions: Kidney Transplant, Myeloma | Phase 4 | Status: COMPLETED